The results showed that while both ADSC-NK and ADSC-NKE were able to kill each of these 7 cancer cell lines, ADSC-NKE was significantly more potent than ADSC-NK in all instances and even more potent than NKL in certain instances (i.e., against PC3 and LnCap) (Fig. 3B). Here, GLIS2 is linked to cancer.